Skip to content

Effect of Masanumasik Garbha Sthapak Granules in Antenatal Care.

Clinical study of Masanumasik Garbha Sthapak Granules with special reference to Antenatal care - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080498
Enrollment
60
Registered
2025-02-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Government PG Ayurveda College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The study will include married pregnant women between the ages of 21 and 35 who voluntarily consent to participate. Eligibility criteria require that participants have no history of previous abnormal pregnancies or pregnancies affected by chromosomal abnormalities. Additionally, they must have a hemoglobin (Hb) level of more than 9 g/dl and a blood pressure range between 100/60 mmHg and 130/90 mmHg. Only women presenting with mild to moderate pregnancy symptoms will be considered for inclusion

Exclusion criteria

Exclusion criteria: Patients with high-risk pregnancies, hyperemesis gravidarum, pre-eclampsiagestational diabetes, IUGR, IUD, thyroid malfunction, and other conditions are not willing or able to participate in the study.

Design outcomes

Primary

MeasureTime frame
Give a relief in some symptoms of normal pregnancy like generalised weakness, tiredness, morning sickness anorexia, nausea, vomiting etc. to the patient.Timepoint: 9 months

Secondary

MeasureTime frame
Relief in the symptoms like nausea and vomiting, morning sickness, anorexia, general debility, mood swings, etc.Timepoint: 9 months

Countries

India

Contacts

Public ContactDr ANJANA SAXENA

Government PG Ayurveda College and Hospital

Shashi.ayumc@gmail.com9451680560

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026